Search reports, ask a question, or jump to a page.
The problem
Intervention: Introduction of HPV vaccination for 12-year-old girls into the National Immunization Program using bivalent/quadrivalent vaccine (Scenario 1) or nonavalent vaccine (Scenario 2)
Who it was tested with: 12-year-old girls in Türkiye.
Experience from people who deliver programmes: stories, case studies and lessons learned. Valuable for understanding how and why, and for spotting what to test next, but not a measure of effect.
"The analysis employed the WHO-endorsed PRIME model in Microsoft Excel. Two vaccination strategies were simulated for 12-year-old girls: Scenario 1 (bivalent or quadrivalent vaccine) and Scenario 2 (nonavalent vaccine)." This is a health economic modelling study that projects whether vaccination would be efficient, using established WHO methods to inform policy decisions about immunization program implementation.
Model-based analysis without real-world implementation data; does not include actual vaccination uptake rates, programmatic delivery costs, or equity considerations; assumes stable HPV epidemiology and vaccine efficacy over time.
Across countries and designs
11 studies · 7 countries
